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METHODS: Treatment failure (TF) in children suffering 
from RTI was derived from the German IMS Disease 
Analyzer–mediplus database totalling 20% of all treatments 
with clarithromycin suspension. TF is due to non-sensitivity 
to clarithromycin or incomplete intake of medication (non-
compliance). The TF rate due to non-compliance on the clar-
ithromycin suspension (13.5%) was calculated from the overall
TF rate (20%) minus the average TF rate due to non-sensitivity
(6.5%). The TF rate due to non-compliance on clarithromycin
SipTechnology was 1.75% as estimated from clinical trial.
Resource utilisation data for treatment of RTI and TF were
obtained from a Delphi panel of paediatricians. The analysis was
conducted from the perspective of the German Statutory Health
Insurance (SHI), including direct costs for physician visits, 
laboratory values, drugs and hospitalizations. Cost data were
derived from published sources for the year 2006. One-way sen-
sitivity analyses were performed. RESULTS: The average costs
of TF totalled €118.05 per case. With an RTI incidence of 
about 426,000 cases among German children aged 2–12 years
and a reduction of TF from 20% to 8.25% (remaining TF 
due to non-sensitivity plus non-compliance on clarithromycin 
SipTechnology) for clarithromycin SipTechnology compared to
clarithromycin suspension, the annual cost-savings for the SHI
amount to about €5.9 million. Sensitivity analyses conﬁrm the
robustness of the results. CONCLUSIONS: Due to its improved
compliance and consequently decreased TF rates, the treatment
with clarithromycin SipTechnology is cost-saving for the German
health care system compared to clarithromycin suspension.
PRS10
CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD):
HOSPITALIZATIONS AND COSTS BY SEVERITY OF ILLNESS
O’Brien JA, Duran PA, Caro JJ
Caro Research Institute, Concord, MA, USA
OBJECTIVES: To examine use and cost of inpatient care by
severity of COPD during one year. METHODS: Using
2004–2005 Massachusetts hospital discharge data, a cohort of
patients with COPD (ICD-9 principal diagnosis codes: 491.2X,
492.X, 493.2, 496) assigned to v15APR-DRG 140 (COPD) was
identiﬁed. A COPD inpatient stay proﬁle was established start-
ing with the ﬁrst hospitalization (index stay) at any Massachu-
setts hospital in 2004 and included all subsequent inpatient stays
for COPD within twelve months. Cases were examined by APR-
DRG severity (mild, moderate, major, extreme). Charges (accom-
modations, ancillary services) adjusted by a 0.652 cost-to-charge
ratio, medical inﬂation and geographic factors are reported as
2006 US$ costs. RESULTS: Of the 11,279 patients 60% were
female, mean age was 69 years. More than half (54%) were clas-
siﬁed as moderate severity; 22% as major, 21% as minor and
4% as extreme. For all COPD cases, the mean LOS was 4.7 days
with a mean cost of $6671 per hospital stay. On average, LOS
and cost increased by severity level from 3.5 days at $4745 for
minor cases to 9 days at $15,997 for extreme cases. The inpa-
tient case fatality rate (CFR) during the index stay ranged from
<1% (minor severity) to 18% (extreme severity). During the sub-
sequent year, 5044 (46% of index survivors) had a COPD-
related readmission. The readmission rate was 39% for minor
cases (mean: 2.2; range: 1–15), 39% for moderate cases (mean:
2.1; range: 1–18), 38% for major cases (mean: 2.1; range: 1–12)
and 20% for extreme cases (mean 2.3; range: 1–10). CON-
CLUSION: Almost half of patients receiving inpatient manage-
ment for COPD will require multiple hospital admissions within
a one year period. Severity of illness impacts duration and cost
of hospital stay, inpatient CFR and readmission rate.
RESPIRATORY DISEASES—Health Care Use & 
Policy Studies
PRS11
PERCEPTIONS ABOUT BEHIND-THE-COUNTER AVAILABILITY
OF PSEUDOEPHEDRINE
Shi CW, Ganiats T
UC San Diego, La Jolla, CA, USA
OBJECTIVES: Recent federal legislations has mandated phar-
macies to move pseudoephedrine (PSE) products from over-the-
counter to behind-the-counter. We undertook a qualitative study
that explored the public’s perceptions about this new policy.
METHODS: Ninety participants comprising of physicians,
patients, and pharmacists responded to questions about per-
ceived advantages and disadvantages of this policy, its inﬂuence
on the treatment for a common cold, barriers to implementation,
and personal impacts. Qualitative content analysis was per-
formed through the immersion and crystallization process to
identify emerging themes and salient topics. RESULTS: Advan-
tages included more opportunities for pharmacist counseling,
decreased access to pseudoephedrine by minors, less likelihood
for misuse to occur, and less shoplifting. Disadvantages included
rising prices for other cold remedies, less consumer autonomy,
and more pharmacy workload. Implementation barriers involved
lack of consolidated purchase data between various pharmacies
as well as discrepancies between store versus pharmacy hours of
operation. Impact on treatment of colds consisted of substitution
with other over-the-counter remedies and frequent clinic visits
for prescription drugs. CONCLUSION: This exploratory study
suggested actions that might improve the desired effect of the
pseudoephedrine legislation: 1) establishing a universal system 
of linking purchase data among various pharmacies; 2) reducing
the discrepancy between pharmacies’ and stores’ hours of oper-
ation; 3) providing additional support to help the pharmacy 
staff adapt to their new regulatory roles; 4) enhancing 
public awareness about the policy; and 5) studying the economic
effects of this policy on the costs of cold remedies and health
care expenditures.
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OBJECTIVES: The burden of chronic obstructive pulmonary
disease (COPD) and asthma could be reduced through appro-
priate medication therapy management. This study examines 
the relative propensity of Maryland Medicaid managed care
organization (MMMCO) patients with COPD and asthma or
either alone, to be prescribed ﬂuticasone/salmeterol combination
(FSC). METHODS: All medical and prescription claims for
MMMCO enrollees with a diagnosis of COPD (ICD-9 codes
491, 492, 496) and/or asthma (ICD-9 codes 493) in the primary,
or secondary diagnosis ﬁeld, were retrieved. Study patients were
40 and older, claiming at least one FSC or other COPD drug
with a minimum 30 days supply. The propensity of being pre-
scribed FSC was estimated as a logistic function of patient age,
gender, race, general health (as measured by the Charlson
Comorbidity Index), and diagnosis of COPD and/or asthma.
RESULTS: Out of total 9131 patients, half were African-
American, 70% were female and over half were over 50 years
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old. After adjusting for confounders, patients with COPD and
asthma were twice as likely to use FSC than those with Asthma
along (OR 1.99, 95% CI 1.73–2.29); patients with COPD alone
were 66% less likely to receive FSC than those with Asthma
along (OR 0.34, 95% CI 0.28–0.41). African-Americans were a
third less likely to be prescribed FSC than Caucasians (OR 0.69;
95% CI 0.61–0.78), and females about a third more likely than
males to use FSC (OR 1.35; 95% CI 1.16–1.57). Age was not a
signiﬁcant predictor at the 0.05 level. CONCLUSION: The
propensity to be prescribed FSC is signiﬁcantly higher in patients
with COPD/asthma than those with either disease alone. Race
and gender signiﬁcantly affect access to FSC in MMMCO, even
after adjusting for comorbidities. Cost to the patient was not a
factor, as the copayment was $1 for any prescription.
STROKE—Clinical Outcomes Studies
PST1
EPIDEMIOLOGY AND ECONOMIC BURDEN OF 
STROKE-RELATED RISK FACTORS:A SYSTEMATIC
LITERATURE REVIEW
Balu S1, Dutcher S2, Lee WC2, Joshi AV3, Pashos CL1
1Abt Associates Inc, Lexington, MA, USA, 2Abt Associates Inc,
Bethesda, MD, USA, 3Novo Nordisk Inc, Princeton, NJ, USA
OBJECTIVES: To determine the epidemiological risk factors
associated with stroke, examine their inﬂuence on stroke-related
costs, and identify areas that need further research. METHODS:
A systematic literature search was performed (1996–2006) using
an exhaustive list of relevant search terms to identify articles
published on epidemiology of stroke and associated risk factors,
costs of stroke and economic impact of risk factors on stroke.
Studies were identiﬁed through electronic Medline® and
PubMed® searches. Manual review of bibliographies allowed
determination of additional articles. RESULTS: Out of a total of
41 included studies, 26 studies focused on stroke-associated risk
factors, while 15 studies examined the economic burden of
stroke. Apart from age and race [African-Americans have the
highest per-capita stroke costs ($25,782), followed by Hispanics
($17,201)], hypertension was the most prevalent clinical risk
factor (58.1% to 75%), followed by diabetes. Relative risk for
stroke was higher in women (increase of 2–6.5 fold) as compared
to men (1.5–2 fold) with diabetes. Renal dysfunction, pregnancy,
inﬂammation and infection, depression, chronic headache and
migraine, metabolic syndrome, cancer, and AIDS were other risk
factors identiﬁed. Total cost of stroke in United States was found
to be approximately $58 billion [2006 American Heart Associ-
ation]. Mean total cost per individual approximated $125,000.
Subarachnoid hemorrhage was reported to be the costliest stroke
sub-type. Hospitalizations and medications were the major cost
components in stroke treatment. Studies have linked few risk
factors, such as smoking and higher age, to increased stroke
treatment costs, but the impact of the majority of risk factors on
stroke costs has not been examined. CONCLUSION: Stroke has
a signiﬁcant economic impact on society, due to its morbidity
and mortality burden. However, few studies have examined the
impact of individual stroke-associated risk factors on stroke
costs. Further research demonstrating economic link of common
risk factors with stroke is warranted.
PST2
HOSPITAL-BASED OUTCOMES ASSOCIATED WITH NON-
TRAUMATIC SUBARACHNOID HEMORRHAGE
Van Den Bos J1, Dreyer NA2 Bly AK1, Mehmoud SM1
1Milliman, Denver, CO, USA, 2Outcome, Cambridge, MA, USA
OBJECTIVES: Subarachnoid hemorrhage (SAH) is a rare but
catastrophic event, occurring in ∼10/100,000 people, which may
result in permanent brain damage or death. Although treatment
protocols for surgical or endovascular management of SAH have
been published, widespread differences exist in patient manage-
ment. METHODS: The MedStat Marketscan databases were
used for 2000–2004 to study medical utilization for non-
traumatic SAH. Data included commercially insured and
Medicare-eligible claimants. Hospitalization records were exam-
ined for patients ages 18 and older who had a primary diagno-
sis of SAH (ICD-9 430) without any indication of trauma (n =
3241). If a hospital stay was followed by another hospitalization
which started on the date of discharge, the two were treated as
a single episode of care. Rates of surgical clipping and/or
endovascular coiling (“treatment” to secure the aneurysm), inpa-
tient death rates, day of any surgical treatment, length of stay,
and hospital readmissions were examined. RESULTS: Seventy
percent of admissions for SAH were ages <65, and 35% were
treated. Among those over age 65, only 13% were treated. 14%
of SAH patients died during the initial hospitalization. Mortal-
ity rates were lower for those treated at all ages. Among sur-
vivors treated, 45% were treated on the day of admission, and
about one-third were treated the day after admission. Among
survivors, the median length of stay was 6 days for those without
treatment, and nearly twice as long for patients who were
clipped, coiled or both. 5% of patients were readmitted to hos-
pital, with a median of 17 days between ﬁrst and second admis-
sions. CONCLUSION: Most patients presenting at the hospital
with non-traumatic SAH received no surgical or endovascular
treatment. The 35% treatment rate for SAH. is considerably
lower than in other countries, raising the possibility that patient
treatment may not be optimal in the U.S.
STROKE—Cost Studies
PST3
THE IMPACT OF WIDESPREAD ACCESS TO ORGANIZED
STROKE CARE IN CANADA
Caro JJ1, Huybrechts KF1, Kongnakorn T1, Ozer Stillman I1,
Sharma M2
1Caro Research Institute, Concord, MA, USA, 2The Ottawa Hospital,
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OBJECTIVES: Despite solid evidence, measures for prevention,
treatment and other health practices that could reduce mortal-
ity, disability and costs are not being used routinely in Canada.
An economic model was developed to formally assess the poten-
tial clinical and economic impact of implementing a com-
prehensive stroke program. METHODS: A discrete event
simulation was designed to assess the implications of various
stroke strategies deﬁned in terms of the usage of organized stroke
units and clot-busting therapies, access to rehabilitation, stroke
awareness and prevention campaigns. Stroke incidence, modiﬁed
by whatever prevention practices are analyzed, is applied to the
Canadian population to create the simulated patients with
stroke. Each patient’s management is simulated according to his
characteristics and the interventions available given the strategy
under consideration. Over time, patients are exposed to risks of:
death, new stroke, change in functional level, and transfer to
another location of care. Each event is processed in terms of its
clinical consequences, resource use and cost. Data were obtained
from the Registry of the Canadian Stroke Network, the Cana-
dian Heart Health Survey, Statistics Canada and the Institute for
Clinical and Evaluative Sciences. RESULTS: Implementation of
widespread prevention and awareness campaigns would result in
∼127,000 fewer initial strokes over 20 years. Access to organized
